- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Therapy With Immunoconjugates for Multiple Myeloma
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-06-19
DOI
10.3389/fimmu.2020.01155
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
- (2020) Deepu Madduri et al. BLOOD
- First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
- (2020) Luciano J. Costa et al. BLOOD
- Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
- (2020) Jesus G. Berdeja et al. BLOOD
- First-in-Human Phase 1 Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients With Relapsed and Refractory Multiple Myeloma
- (2020) Ravi Vij et al. CLINICAL CANCER RESEARCH
- Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab
- (2020) Kristine A. Frerichs et al. CLINICAL CANCER RESEARCH
- A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
- (2020) Lijie Xing et al. LEUKEMIA
- CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging
- (2020) Gary A. Ulaner et al. RADIOLOGY
- Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient’s Bedside to Evaluation in Preclinical Models
- (2019) Yasmin Leshem et al. Toxins
- Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
- (2019) Suzanne Trudel et al. Blood Cancer Journal
- Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
- (2019) A. Keith Stewart et al. Blood Cancer Journal
- GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
- (2019) Eric L. Smith et al. Science Translational Medicine
- Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models
- (2019) Zoë Shancer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib
- (2019) Satoko Oka et al. LEUKEMIA & LYMPHOMA
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- (2019) Ujjawal H. Gandhi et al. LEUKEMIA
- Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma
- (2019) Sundar Jagannath et al. Clinical Lymphoma Myeloma & Leukemia
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors
- (2019) Wojciech Dawicki et al. OncoImmunology
- Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells
- (2019) Peggy Liu-Kreyche et al. Frontiers in Pharmacology
- The Alpha Emitter Astatine-211 Targeted to CD38 can Eradicate Multiple Myeloma in a Disseminated Disease Model
- (2019) Shyril O'Steen et al. BLOOD
- Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
- (2019) Bo Yu et al. Journal of Hematology & Oncology
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies
- (2019) Nirav N. Shah et al. BLOOD
- Preclinical Development of a Bcma Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy
- (2019) Andrew Hau et al. BLOOD
- Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies
- (2019) Lingna Li et al. BLOOD
- Synergistic Activity of Belantamab Mafodotin (anti-BCMA immuno-conjugate) with PF-03084014 (gamma-secretase inhibitor) in Bcma-Expressing Cancer Cell Lines
- (2019) Stephen Eastman et al. BLOOD
- Preclinical evaluation of the new GPRC5DxCD3 (JNJ-7564) bispecific antibody for the treatment of multiple myeloma
- (2019) Christie Verkleij et al. Clinical Lymphoma Myeloma & Leukemia
- MEDI2228, a novel BCMA pyrrolobenzodiazepine antibody drug conjugate, overcomes drug resistance and synergizes with bortezomib and DNA damage response inhibitors in multiple myeloma
- (2019) Yu-Tzu Tai et al. Clinical Lymphoma Myeloma & Leukemia
- Critical Issues in the Development of Immunotoxins for Anticancer Therapy
- (2019) Ji-Sun Kim et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma
- (2019) Priya Choudhry et al. LEUKEMIA
- Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma
- (2019) Robert Chen et al. CLINICAL CANCER RESEARCH
- 212Pb Alpha-Radioimmunotherapy targeting CD38 in Multiple Myeloma: a preclinical study.
- (2019) Isabelle QUELVEN et al. JOURNAL OF NUCLEAR MEDICINE
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins
- (2018) Ronit Mazor et al. AMERICAN JOURNAL OF PATHOLOGY
- Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma
- (2018) Enrico Caserta et al. BLOOD
- Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody–Drug Conjugates
- (2018) Hui Zhao et al. CANCER RESEARCH
- Resistance to Antibody–Drug Conjugates
- (2018) Sara García-Alonso et al. CANCER RESEARCH
- Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model
- (2018) Hans D. Menssen et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- T cell senescence and CAR-T cell exhaustion in hematological malignancies
- (2018) Dimitri Kasakovski et al. Journal of Hematology & Oncology
- Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
- (2018) Robert J. Kreitman et al. LEUKEMIA
- OUP accepted manuscript
- (2018) PROTEIN ENGINEERING DESIGN & SELECTION
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Abstract 5619: Additional mechanisms of action of SGN-CD48A in multiple myeloma and improved antitumor activity in combination with daratumumab
- (2018) Devra J. Olson et al. CANCER RESEARCH
- Abstract LB-295: MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potentin vivoactivity across a spectrum of hematological malignancies
- (2018) Noel R. Monks et al. CANCER RESEARCH
- A Phase I Study to Assess the Safety and Pharmacokinetics of Single-Agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56 Positive Multiple Myeloma
- (2018) Sikander Ailawadhi et al. Clinical Lymphoma Myeloma & Leukemia
- HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma.
- (2018) Andreas Pahl et al. JOURNAL OF CLINICAL ONCOLOGY
- IRF4 in multiple myeloma—Biology, disease and therapeutic target
- (2018) Alessandro Agnarelli et al. LEUKEMIA RESEARCH
- Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
- (2018) Suzanne Trudel et al. LANCET ONCOLOGY
- Preclinical assessment of an antibody–PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells
- (2018) Krista Kinneer et al. LEUKEMIA
- Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001
- (2018) Cristina L. Abrahams et al. Oncotarget
- Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy
- (2018) Lorenzo Mortara et al. Frontiers in Immunology
- Design, synthesis and evaluation of anti-CD38 antibody drug conjugate based on Daratumumab and maytansinoid
- (2018) Xinfu Zhang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
- (2017) Kurt Schönfeld et al. Journal of Hematology & Oncology
- Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
- (2017) Anchal Ghai et al. JOURNAL OF NUCLEAR MEDICINE
- Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients
- (2017) T K Bera et al. LEUKEMIA
- Antibody drug conjugates: lessons from 20 years of clinical experience
- (2016) A. W. Tolcher ANNALS OF ONCOLOGY
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Monoclonal antibodies — A new era in the treatment of multiple myeloma
- (2016) Tomas Jelinek et al. BLOOD REVIEWS
- Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma
- (2016) Lydia Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Abstract 1195: SGN-CD352A: A novel humanized anti-CD352 antibody-drug conjugate for the treatment of multiple myeloma
- (2016) Tim Lewis et al. CANCER RESEARCH
- Abstract 595: Next-generation engineered toxin bodies: CD38, PD-L1 and HER2 targeted ETBs
- (2016) Sangeetha Rajagopalan et al. CANCER RESEARCH
- Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions
- (2016) Franziska Bootz et al. DRUG DISCOVERY TODAY
- Immunogenicity of therapeutic recombinant immunotoxins
- (2016) Ronit Mazor et al. IMMUNOLOGICAL REVIEWS
- Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells
- (2016) Daniel W. Sherbenou et al. JOURNAL OF CLINICAL INVESTIGATION
- T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
- (2016) Claudia Zelle-Rieser et al. Journal of Hematology & Oncology
- Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade
- (2016) H Suen et al. LEUKEMIA
- Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma
- (2016) Alex Vasuthasawat et al. mAbs
- CD74 is a novel transcription regulator
- (2016) Naama Gil-Yarom et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A
- (2016) Gilad Kaplan et al. Toxins
- Role of IL-2 in cancer immunotherapy
- (2016) Tao Jiang et al. OncoImmunology
- Chemotherapy and Stem Cell Transplantation Increase p16 INK4a Expression, a Biomarker of T-cell Aging
- (2016) William A. Wood et al. EBioMedicine
- Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity
- (2016) Sarah L. Pogue et al. PLoS One
- Immuno-targeting the multifunctional CD38 using nanobody
- (2016) Ting Li et al. Scientific Reports
- A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, yttrium-90 ibritumomab tiuxetan) for Patients with Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma
- (2015) Limin Gao et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma
- (2015) A Rosko et al. BONE MARROW TRANSPLANTATION
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-CD138-Targeted Interferon Is a Potent Therapeutic Against Multiple Myeloma
- (2015) Esther M. Yoo et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
- (2015) Joshua Seth Eaton et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Current Role of Radiation Therapy for Multiple Myeloma
- (2015) Giampaolo Talamo et al. Frontiers in Oncology
- α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma
- (2015) Katharina Teiluf et al. Oncotarget
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Immunotoxins for leukemia
- (2014) A. S. Wayne et al. BLOOD
- Side Effects of Cytokines Approved for Therapy
- (2014) Brian A. Baldo DRUG SAFETY
- IFN- Skews Monocytes into CD56+-Expressing Dendritic Cells with Potent Functional Activities In Vitro and In Vivo
- (2014) C. Papewalis et al. JOURNAL OF IMMUNOLOGY
- Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers
- (2014) C. Alewine et al. MOLECULAR CANCER THERAPEUTICS
- Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes
- (2014) R. Mazor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Radioimmunoconjugates for the Treatment of Cancer
- (2014) Françoise Kraeber-Bodéré et al. SEMINARS IN ONCOLOGY
- The novel immunotoxin HM1.24-ETA′ induces apoptosis in multiple myeloma cells
- (2014) M Staudinger et al. Blood Cancer Journal
- Expression of Myeloid Antigen in Neoplastic Plasma Cells Is Related to Adverse Prognosis in Patients with Multiple Myeloma
- (2014) Hyoeun Shim et al. Biomed Research International
- A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies
- (2013) D. J. Green et al. CANCER RESEARCH
- 213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma
- (2013) M. Cherel et al. JOURNAL OF NUCLEAR MEDICINE
- Ribosome-inactivating proteins
- (2013) Matthew J Walsh et al. Virulence
- Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma
- (2012) B. A. Walker et al. BLOOD
- Darwinian evolution and tiding clones in multiple myeloma
- (2012) N. J. Bahlis BLOOD
- Clonal competition with alternating dominance in multiple myeloma
- (2012) J. J. Keats et al. BLOOD
- Abstract 770: Lorvotuzumab mertansine (IMGN901) immune effector activity and its effect on human NK cells
- (2012) Anna Skaletskaya et al. CANCER RESEARCH
- Molecular Pathways: Targeted -Particle Radiation Therapy
- (2012) K. E. Baidoo et al. CLINICAL CANCER RESEARCH
- Immunocytokines: a novel class of potent armed antibodies
- (2012) Nadine Pasche et al. DRUG DISCOVERY TODAY
- Stimulation of NF- B Activity by the HIV Restriction Factor BST2
- (2012) A. Tokarev et al. JOURNAL OF VIROLOGY
- FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma
- (2012) K. Elkins et al. MOLECULAR CANCER THERAPEUTICS
- Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients
- (2012) Caroline Rousseau et al. TUMOR BIOLOGY
- Identification of Alternatively Translated Tetherin Isoforms with Differing Antiviral and Signaling Activities
- (2012) Luis J. Cocka et al. PLoS Pathogens
- Preclinical studies on targeted delivery of multiple IFN 2b to HLA-DR in diverse hematologic cancers
- (2011) E. A. Rossi et al. BLOOD
- Abstract 2596: Targeted delivery of doxorubicin conjugated with anti-matriptase antibody to treat multiple myeloma
- (2011) Joseph R. Bertino et al. CANCER RESEARCH
- Direct Effects of Type I Interferons on Cells of the Immune System
- (2011) S. Hervas-Stubbs et al. CLINICAL CANCER RESEARCH
- Use of Radioactive Iodine for Thyroid Cancer
- (2011) Megan R. Haymart JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans
- (2011) E. Erikson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status
- (2010) J. Quinn et al. BLOOD
- A Bispecific Antibody-IFN 2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells
- (2010) E. A. Rossi et al. CANCER RESEARCH
- Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis
- (2009) Dongqing Cai et al. BMC CANCER
- Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma
- (2009) A. Labrinidis et al. CLINICAL CANCER RESEARCH
- Effects of aging on T cell function
- (2009) Laura Haynes et al. CURRENT OPINION IN IMMUNOLOGY
- Human natural killer cells
- (2008) M. A. Caligiuri BLOOD
- A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
- (2008) J. E. Weldon et al. BLOOD
- HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody
- (2008) Wei Wang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin
- (2008) N. Jouvenet et al. JOURNAL OF VIROLOGY
- Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma
- (2008) Maria Kraj et al. LEUKEMIA & LYMPHOMA
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
- Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
- (2008) Stuart J. D. Neil et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started